Raziskave nove klinike Cleveland prvič kažejo, da lahko ibrutinib (ibrutinib), odobren s strani FDA, za limfom in levkemijo pomaga pri zdravljenju najpogostejših in smrtonosnih možganskih tumorjev in se nekega dne lahko uporablja pri bolnikih z glioblastomom in izboljša stopnjo preživetja.
Po poročilu Ameriškega združenja možganskih tumorjev je stopnja preživetja glioblastoma zelo nizka, mediana preživetja bolnikov, ki se zdravijo s standardnim zdravljenjem, pa je manj kot 15 mesecev. Glioblastom je najbolj smrtonosni primarni možganski tumor in je zelo odporen na sedanje zdravljenje. Nujno je treba tem pacientom čim prej zagotoviti novo zdravljenje.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumorji in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
